Literature DB >> 15793701

The Epsin 4 gene on chromosome 5q, which encodes the clathrin-associated protein enthoprotin, is involved in the genetic susceptibility to schizophrenia.

Jonathan Pimm1, Andrew McQuillin, Srinivasa Thirumalai, Jacob Lawrence, Digby Quested, Nicholas Bass, Graham Lamb, Helen Moorey, Susmita R Datta, Gursharan Kalsi, Allison Badacsonyi, Katie Kelly, Jenny Morgan, Bhaskar Punukollu, David Curtis, Hugh Gurling.   

Abstract

Chromosome 5q33 is a region that has previously shown good evidence of linkage to schizophrenia, with four LOD scores >3.00 in independent linkage studies. We studied 450 unrelated white English, Irish, Welsh, and Scottish research subjects with schizophrenia and 450 ancestrally matched supernormal controls. Four adjacent markers at the 5' end of the Epsin 4 gene showed significant evidence of linkage disequilibrium with schizophrenia. These included two microsatellite markers, D5S1403 (P=.01) and AAAT11 (P=.009), and two single-nucleotide-polymorphism markers within the Epsin 4 gene, rs10046055 (P=.007) and rs254664 (P=.01). A series of different two- and three-marker haplotypes were also significantly associated with schizophrenia, as confirmed with a permutation test (HapA, P=.004; HapB, P=.0005; HapC, P=.007; and HapD, P=.01). The Epsin 4 gene encodes the clathrin-associated protein enthoprotin, which has a role in transport and stability of neurotransmitter vesicles at the synapses and within neurons. A genetically determined abnormality in the structure, function, or expression of enthoprotin is likely to be responsible for genetic susceptibility to a subtype of schizophrenia on chromosome 5q33.3.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15793701      PMCID: PMC1199380          DOI: 10.1086/430095

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  14 in total

1.  New DNA markers with increased informativeness show diminished support for a chromosome 5q11-13 schizophrenia susceptibility locus and exclude linkage in two new cohorts of British and Icelandic families.

Authors:  G Kalsi; B Mankoo; D Curtis; R Sherrington; G Melmer; J Brynjolfsson; T Sigmundsson; T Read; P Murphy; H Petursson; H Gurling
Journal:  Ann Hum Genet       Date:  1999-05       Impact factor: 1.670

2.  Model-free analysis and permutation tests for allelic associations.

Authors:  J H Zhao; D Curtis; P C Sham
Journal:  Hum Hered       Date:  2000 Mar-Apr       Impact factor: 0.444

3.  Genome-wide multipoint linkage analyses of multiplex schizophrenia pedigrees from the oceanic nation of Palau.

Authors:  B Devlin; S-A Bacanu; K Roeder; F Reimherr; P Wender; B Galke; D Novasad; A Chu; K TCuenco; S Tiobek; C Otto; W Byerley
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

4.  Solution structure of the epsin N-terminal homology (ENTH) domain of human epsin.

Authors:  Seizo Koshiba; Takanori Kigawa; Akira Kikuchi; Shigeyuki Yokoyama
Journal:  J Struct Funct Genomics       Date:  2002

5.  GENECOUNTING: haplotype analysis with missing genotypes.

Authors:  Jing Hua Zhao; Sebastien Lissarrague; Laurent Essioux; Pak Chung Sham
Journal:  Bioinformatics       Date:  2002-12       Impact factor: 6.937

6.  A quick and simple method for detecting subjects with abnormal genetic background in case-control samples.

Authors:  D Curtis; B V North; H M D Gurling; E Blaveri; P C Sham
Journal:  Ann Hum Genet       Date:  2002-05       Impact factor: 1.670

7.  Localization of a susceptibility locus for schizophrenia on chromosome 5.

Authors:  R Sherrington; J Brynjolfsson; H Petursson; M Potter; K Dudleston; B Barraclough; J Wasmuth; M Dobbs; H Gurling
Journal:  Nature       Date:  1988-11-10       Impact factor: 49.962

8.  Evidence suggestive of a locus on chromosome 5q31 contributing to susceptibility for schizophrenia in German and Israeli families by multipoint affected sib-pair linkage analysis.

Authors:  S G Schwab; G N Eckstein; J Hallmayer; B Lerer; M Albus; M Borrmann; D Lichtermann; M A Ertl; W Maier; D B Wildenauer
Journal:  Mol Psychiatry       Date:  1997-03       Impact factor: 15.992

9.  Monte Carlo tests for associations between disease and alleles at highly polymorphic loci.

Authors:  P C Sham; D Curtis
Journal:  Ann Hum Genet       Date:  1995-01       Impact factor: 1.670

10.  Enthoprotin: a novel clathrin-associated protein identified through subcellular proteomics.

Authors:  Sylwia Wasiak; Valerie Legendre-Guillemin; Rosa Puertollano; Francois Blondeau; Martine Girard; Elaine de Heuvel; Daniel Boismenu; Alexander W Bell; Juan S Bonifacino; Peter S McPherson
Journal:  J Cell Biol       Date:  2002-09-03       Impact factor: 10.539

View more
  23 in total

Review 1.  Translational research in central nervous system drug discovery.

Authors:  Orest Hurko; John L Ryan
Journal:  NeuroRx       Date:  2005-10

2.  FBXL21 association with schizophrenia in Irish family and case-control samples.

Authors:  Xiangning Chen; Xu Wang; Cuie Sun; Qi Chen; F Anthony O'Neill; Dermot Walsh; Ayman Fanous; Kenneth S Kendler
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-10-05       Impact factor: 3.568

3.  Analysis of protocadherin alpha gene enhancer polymorphism in bipolar disorder and schizophrenia.

Authors:  Erika Pedrosa; Radu Stefanescu; Benjamin Margolis; Oriana Petruolo; Yungtai Lo; Karen Nolan; Tomas Novak; Pavla Stopkova; Herbert M Lachman
Journal:  Schizophr Res       Date:  2008-05-27       Impact factor: 4.939

4.  Interaction between interleukin 3 and dystrobrevin-binding protein 1 in schizophrenia.

Authors:  Todd L Edwards; Xu Wang; Qi Chen; Brandon Wormly; Brien Riley; F Anthony O'Neill; Dermot Walsh; Marylyn D Ritchie; Kenneth S Kendler; Xiangning Chen
Journal:  Schizophr Res       Date:  2008-09-18       Impact factor: 4.939

5.  Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia.

Authors:  Hugh M D Gurling; Hugo Critchley; Susmita R Datta; Andrew McQuillin; Ekaterina Blaveri; Srinivasa Thirumalai; Jonathan Pimm; Robert Krasucki; Gursharan Kalsi; Digby Quested; Jacob Lawrence; Nicholas Bass; Khalid Choudhury; Vinay Puri; Owen O'Daly; David Curtis; Douglas Blackwood; Walter Muir; Anil K Malhotra; Robert W Buchanan; Catriona D Good; Richard S J Frackowiak; Raymond J Dolan
Journal:  Arch Gen Psychiatry       Date:  2006-08

6.  Case-case genome-wide association analysis shows markers differentially associated with schizophrenia and bipolar disorder and implicates calcium channel genes.

Authors:  David Curtis; Anna E Vine; Andrew McQuillin; Nicholas James Bass; Ana Pereira; Radhika Kandaswamy; Jacob Lawrence; Adebayo Anjorin; Khalid Choudhury; Susmita R Datta; Vinay Puri; Robert Krasucki; Jonathan Pimm; Srinivasa Thirumalai; Digby Quested; Hugh M D Gurling
Journal:  Psychiatr Genet       Date:  2011-02       Impact factor: 2.458

7.  Failure to confirm an association between Epsin 4 and schizophrenia in a Japanese population.

Authors:  Misty Richards; Yoshimi Iijima; Tomoko Shizuno; Yoko Kamegaya; Hiroaki Hori; Mayu Omori; Kunimasa Arima; Osamu Saitoh; Hiroshi Kunugi
Journal:  J Neural Transm (Vienna)       Date:  2008-08-12       Impact factor: 3.575

8.  Polymorphisms in the GRIA1 gene region in psychotic bipolar disorder.

Authors:  Berit Kerner; Anna J Jasinska; Joseph DeYoung; Maricel Almonte; Oi-Wa Choi; Nelson B Freimer
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-01-05       Impact factor: 3.568

9.  MEGF10 association with schizophrenia.

Authors:  Xiangning Chen; Xu Wang; Qi Chen; Vernell Williamson; Edwin van den Oord; Brion S Maher; F Anthony O'Neill; Dermot Walsh; Kenneth S Kendler
Journal:  Biol Psychiatry       Date:  2008-01-07       Impact factor: 13.382

Review 10.  Zebrafish as a genetic model in biological and behavioral gerontology: where development meets aging in vertebrates--a mini-review.

Authors:  Shuji Kishi; Barbara E Slack; Junzo Uchiyama; Irina V Zhdanova
Journal:  Gerontology       Date:  2009-07-27       Impact factor: 5.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.